Stock Events

Stock Events

TuHURA Biosciences 

€1.94
114
+€0.1+5.43% Monday 06:03

Statistics

Day High
1.94
Day Low
1.94
52W High
3.6
52W Low
0.37
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Next
-0.1
0.23
0.56
0.9
Expected EPS
-0.10240679999999999
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PL3.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Marker Therapeutics
MRKR
Mkt Cap26.01M
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, focusing on novel cancer therapies that are in direct competition with Kintara's products.
SELLAS Life Sciences Group
SLS
Mkt Cap909.75M
SELLAS Life Sciences Group, Inc. focuses on cancer immunotherapies, particularly in advancing novel cancer vaccines that compete with Kintara's therapeutic strategies.
Hepion Pharmaceuticals
HEPA
Mkt Cap1.83M
Hepion Pharmaceuticals, Inc. is engaged in the development of drug therapies for cancer, among other diseases, positioning it as a competitor.
CytomX Therapeutics
CTMX
Mkt Cap903.62M
CytomX Therapeutics, Inc. develops antibody therapeutics for cancer treatment, directly competing with Kintara's focus on innovative cancer therapies.

About

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Show more...
CEO
Dr. James A. Bianco M.D.
Employees
22
Country
United States
ISIN
US8989201038

Listings

F
DE
PL3.F
STU
DE
PL3.STU
MU
DE
PL3.MU
XNAS
US
HURA

0 Comments

Share your thoughts

FAQ

What is TuHURA Biosciences stock price today?▼
The current price of PL3.MU is €1.94 EUR — it has increased by +5.43% in the past 24 hours. Watch TuHURA Biosciences stock price performance more closely on the chart.
What is TuHURA Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange TuHURA Biosciences stocks are traded under the ticker PL3.MU.
Is TuHURA Biosciences stock price growing?▼
PL3.MU stock has fallen by -0.51% compared to the previous week, the month change is a +36.62% rise, over the last year TuHURA Biosciences has showed a -44.25% decrease.
When is the next TuHURA Biosciences earnings date?▼
TuHURA Biosciences is going to release the next earnings report on May 12, 2026.
How many employees does TuHURA Biosciences have?▼
As of May 06, 2026, the company has 22 employees.
In which sector is TuHURA Biosciences located?▼
TuHURA Biosciences operates in the Other sector.
When did TuHURA Biosciences complete a stock split?▼
The last stock split for TuHURA Biosciences was on October 18, 2024 with a ratio of 1:1.
Where is TuHURA Biosciences headquartered?▼
TuHURA Biosciences is headquartered in Tampa, United States.